Although BRAFV600E Inhibitors are extremely effective at treating cancer, their sustainability is constrained by RTKs, RAS activation, or secondary BRAF mutations (Nazarian et al. 2010; Poulikakos et al. 2011). This evidence concerns the gene BRAF and cancer.